| Similar Articles |
 |
Chemistry World January 25, 2013 Rajesh Parishwad |
Indian supreme court's anger over unregulated clinical trials The fledgling clinical trials industry in India has been hit by recent revelations of a lack of regulation. Now, the country's supreme court has criticized the body that oversees clinical trials for its inaction in the face of these unethical practices.  |
Chemistry World October 15, 2013 Dinsa Sachan |
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed.  |
Chemistry World August 16, 2013 Dinsa Sachan |
Indian U-turn on diabetes drug ban In June the Indian government suspended the popular diabetes drug, pioglitazone, over safety concerns only to revoke the suspension a little over a month later.  |
Pharmaceutical Executive April 1, 2014 Subramanian et al. |
"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India.  |
Chemistry World November 12, 2013 Dinsa Sachan |
Rough patch for India's clinical trial industry The Indian clinical trial industry is beset by uncertainty. Campaigners have petitioned the courts claiming that drug companies are exploiting poor people and this has led to more than 100 trials being put on hold.  |
Chemistry World January 7, 2014 Angeli Mehta |
Flu drug stockpile may be worthless The case for spending hundreds of millions of pounds stockpiling antivirals for use in a flu pandemic is based on 'judgement rather than on evidence of their effectiveness', according to a parliamentary committee.  |
Chemistry World August 5, 2014 Dinsa Sachan |
Price caps provoke lawsuits from Indian pharma industry The Indian pharma industry is engaged in a pitched battle with the drug price regulator that recently brought certain drugs under price control.  |
Chemistry World September 6, 2013 Dinsa Sachan |
Another drug suspension overturned in India An Indian high court has quashed the suspension of a popular antidepressant. This comes shortly after the suspension of the diabetes drug pioglitazone was overturned.  |
The Motley Fool June 29, 2010 Brian Orelli |
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting.  |
Chemistry World September 18, 2008 James Mitchell Crow |
Ranbaxy hit by US drug ban The US Food and Drug Administration (FDA) has banned the import of more than 30 drugs made by Ranbaxy, India's largest drugmaker.  |
Chemistry World September 17, 2010 Andrew Turley |
Free trade could throttle generics from India International agreements on intellectual property threaten the flow of generic HIV drugs from India to developing countries, according to a new report.  |
The Motley Fool May 14, 2007 Mike Havrilla |
A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.  |
Chemistry World October 8, 2014 Phillip Broadwith |
EMA finalizes trial transparency rules The European Medicines Agency has finalized its policy for sharing data from clinical trials.  |
Pharmaceutical Executive September 1, 2005 Sarah Houlton |
Global Report: Kids 'R' EU After years of delay, the European Parliament is ready to vote on pediatric-testing legislation.  |
Chemistry World April 30, 2014 Emma Stoye |
New Zealand in legal highs U-turn Politicians in New Zealand have decided to ban designer drugs from sale in the country, reversing an earlier decision to approve low risk drugs while new laws are put in place.  |
BusinessWeek April 18, 2005 Manjeet Kripalani |
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.  |
Chemistry World March 4, 2013 Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.  |
The Motley Fool July 8, 2008 Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.  |
Chemistry World May 27, 2015 Phillip Broadwith |
Label laundry It's been an interesting month in the world of off-label pharmaceuticals.  |
The Motley Fool March 22, 2010 Brian Orelli |
Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.  |
Pharmaceutical Executive May 1, 2005 Sarah Houlton |
Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues.  |
The Motley Fool December 31, 2007 Brian Lawler |
The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.  |
Chemistry World July 25, 2012 |
Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.  |
Chemistry World December 8, 2006 |
Expert Guidance on Clinical Trial Safety Clinical trial design in the UK is due for a shake up following the recommendations of an expert group commissioned in light of a disastrous trial that left six subjects fighting for their lives.  |
Chemistry World October 17, 2014 Dinsa Sachan |
Indian manufacturers hit back over quality claims The Indian pharmaceutical industry has asked its government to sue authors of a study published by the US National Bureau of Economic Research in early September.  |
Pharmaceutical Executive July 3, 2007 |
Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.  |
The Motley Fool May 10, 2005 Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice?  |
Investment Advisor September 2008 |
Asset Allocation, August 2008 Monthly recommendations from the asset allocation panel.  |
The Motley Fool September 6, 2005 Stephen D. Simpson |
FDA's Eye on 2 Potential Blockbusters This week, FDA advisory panels will consider the marketing approval applications of Exubera, the inhaled insulin from Pfizer/Sanofi/Nektar, and Pargluva, the dual PPAR agonist, taken in pill form, from Bristol-Myers and Merck. Investors, take note.  |
Wired March 2006 Jennifer Kahn |
A Nation of Guinea Pigs There's a new outsourcing boom in South Asia - and a billion people are jockeying for the jobs. How India became the global hot spot for drug trials.  |
Registered Rep. May 29, 2007 Kristen French |
Spitzer Forms Panel to Clean up NY Regulation Governor Eliot Spitzer is forming a panel to streamline regulations and make New York more competitive with London, but without sacrificing investor protection.  |
Pharmaceutical Executive March 1, 2012 Ron Cohen |
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.  |
The Motley Fool November 30, 2007 Brian Orelli |
Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way.  |
Investment Advisor July 2008 |
Asset Allocation, July 2008 Monthly recommendations from IA's asset allocation panel  |
Investment Advisor June 2008 |
Asset Allocation, June 2008 Monthly recommendations from this publication's asset allocation panel.  |
Investment Advisor August 2008 |
Asset Allocation, August 2008 Monthly recommendations from this publication's asset allocation panel.  |
The Motley Fool July 12, 2004 Brian Gorman |
India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers.  |
Pharmaceutical Executive January 1, 2007 Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges.  |
Pharmaceutical Executive September 1, 2008 Patrick Clinton |
Attack of the Junk The United States makes the best medicines in the world. In days to come, that could be a problem.  |
Managed Care April 2007 MargaretAnn Cross |
Do P&T Committees Have Enough Power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?  |
Chemistry World May 23, 2012 Andy Extance |
Drug watchdogs mark out global territory The US Food and Drug Administration has published plans to ensure that American citizens continue to enjoy access to safe drugs, even as the regulatory pressures of globalization grow.  |
The Motley Fool September 12, 2005 M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.  |
The Motley Fool March 28, 2005 Brian Gorman |
A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities.  |
Pharmaceutical Executive January 1, 2012 Jill Wechsler |
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.  |
BusinessWeek March 7, 2005 John Carey |
Side Effects Of The Drug Scares New fears give rise to a more honest look at the risks for a pill-popping nation.  |
Chemistry World March 20, 2012 Rajesh Parishwad |
India Green Lights Production of Patented Cancer Drug For the first time India has invoked a 'compulsory license' clause to cut the cost of a patented anti-cancer drug by allowing another company to manufacture the therapy.  |
Chemistry World July 2008 William Bains |
Beyond shareholder returns The author offers a new model for the pharmaceutical industry  |
BusinessWeek August 8, 2005 Manjeet Kripalani |
How A Factory Became A Flash Point Violence at a Honda plant highlights India's outdated labor laws and rattles foreign investors.  |
Chemistry World March 17, 2014 Phillip Broadwith |
UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April.  |
The Motley Fool May 21, 2010 Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.  |